Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical

RARE | NASDAQ
Chart Builder DCF Calculator
$15.90
-$0.18 (-1.12%)
At close: Nov 16, 2026, 4:00 PM ET
$15.85
-$0.05 (-0.31%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.12%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
46.9
-1.5 pts
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #347/1021 (Top 34%)

Key Statistics

Market Data

Market Cap $1.62B
1D Range
15.79 16.39
52W Range
12.88 36.54

Valuation (TTM)

PE -3.06
PB -4.31
EV/EBITDA -6.09

Valuation (NTM)

Forward PE 86.63
Forward PEG 0.04
Price Target $23.00
Loading financial charts...

Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations sp...

Sector Healthcare
Industry Biotechnology
Employees 1,371
IPO Date Jan 31, 2014
Fiscal Year January - December

Latest News

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

4 days ago · seekingalpha.com

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold
Ultragenyx to Participate at Investor Conferences in London

5 days ago · globenewswire.com

Ultragenyx to Participate at Investor Conferences in London
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot

13 days ago · seekingalpha.com

Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

13 days ago · marketbeat.com

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

13 days ago · zacks.com

Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

13 days ago · zacks.com

Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

13 days ago · globenewswire.com

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

20 days ago · globenewswire.com

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

20 days ago · prnewswire.com

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Earnings

Latest Earnings
Nov 3, 2026
EPS
-$1.16
Miss -5.45%
REV
$173M
Miss -5.20%
Next Earnings
Feb 11, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
17
Consensus
Buy
Price Target
$23.00
Upside
+44.65%
Buy (9)
Hold (8)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.